Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-01-17
2003-12-02
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S741000, C514S732000, C514S335000
Reexamination Certificate
active
06656960
ABSTRACT:
BACKGROUND OF THE INVENTION
Minimally invasive direct coronary artery bypass (MIDCAB) surgery, both via sternotomy and alternative incisions, is a substantially revolutionary development in surgery for allowing bypass surgery to be conducted on a beating heart. However, beating heart surgery shows an undesirably higher rate of early graft failure than conventional coronary artery bypass procedures using cardiopulmonary bypass and cardioplegia. The technical difficulty of sewing the coronary artery anastomosis on a beating heart is likely an important factor in this difference in outcome between the two techniques. Controlled intermittent asystole (CIA) during brief intervals required for placing anastomotic sutures is suitable for improving the precision of coronary anastomoses performed on a beating heart and reducing graft failure while increasing ease of operation.
Cardiopulmonary bypass (CPB) and chemical arrest using cardioplegia solutions have traditionally provided surgeons with optimal operative conditions: hemodynamic control and cardiac quiescence. This optimal field has contributed to technical success in increasingly complex cardiac surgical operations. However, there has been recent interest in performing coronary artery bypass surgery without either complete cardiopulmonary bypass or cardioplegia. The quality of the distal anastomosis is a primary concern among cardiac surgeons who observe and perform coronary artery bypass graft (CABG) procedures unaided by cardioplegic arrest and cardiopulmonary bypass. Coronary artery bypass graft failure rates reported with minimally invasive direct coronary artery bypass range from 3.8 to 8.9%, while traditional CABG on CPB has a reported anastomotic failure rate of 0.12%. This may reflect a difference in anastomotic precision between MIDCAB and CPB-aided CABG. Although the benefits of avoiding extracorporeal circulation and global cardioplegia in beating heart procedures are important, they do not outweigh the performance of an optimal coronary anastomosis.
The key difference in the anastomotic results between conventional CABG and beating heart CABG is related to achieving elective asystole during construction of the distal anastomosis. Cardiac motion can be minimized during MIDCAB procedures via pharmacologic bradycardia (adenosine, &bgr; blockade) and mechanical stabilization using various devices. Although these techniques do improve operative conditions, they only approximate the advantages of elective asystole achieved with CPB and cardioplegia.
Applicants show that a state of controlled intermittent asystole (CIA) is produced off CPB, which provides a major advantage otherwise gained by cardioplegic arrest on CPB. In particular, CIA is achieved using unilateral (or bilateral) vagus nerve stimulation coupled with pharmacologic suppression of electromechanical escape activity.
Applicants demonstrate that elective, controlled intermittent asystole is produced by vagus nerve stimulation after treatment with an acetylcholinesterase inhibitor, a &bgr;-adrenergic receptor blocker, or a calcium channel blocker, or combinations thereof.
REFERENCES:
patent: 5330507 (1994-07-01), Schwartz
patent: 5651378 (1997-07-01), Matheny et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5889033 (1999-03-01), Kaminski
patent: 6043273 (2000-03-01), Duhaylongsod
patent: 6060454 (2000-05-01), Duhaylongsod
patent: 6087394 (2000-07-01), Duhaylongsod
patent: 6101412 (2000-08-01), Duhaylongsod
patent: 6127410 (2000-10-01), Duhaylongsod
patent: 6141589 (2000-10-01), Duhaylongsod
patent: 9890156 (1998-08-01), None
patent: 1051168 (2000-11-01), None
patent: WO 9907354 (1999-02-01), None
Bufkin, et al., “Controlled Intermittent Asystole: Pharmacologic Potentiation of Vagal-Induced Asystole,”Ann. Thorac. Surg., 1998;66: pp. 1185-1190.
DiPiro, et al., “Pharmacotherapy: A Pathophysiologic Approach;” Elsevier, New York; pp. 153-157, (1989).
Goodman and Gilman's,The Pharmacological Basis of Therapeutics(6th Ed.), MacMillan Publishing Co., Inc., New York, pp. 93-94 and 104-108 (1980).
Matheny, et al., “Vagus Nerve Stimulation as a Method to Temporarily Slow or Arrest the Heart,”Ann. Thorac. Surg., 1997:63: pp. 528-529.
Thompson, et al., “Bradycardia Induced by Intravascular Versus Direct Stimulation of the Vagus Nerve,”Ann. Thorac. Surg., 1998;65: 637-42.
Criares Theodore J.
Emory University
Jiang S.
Kilpatrick & Stockton LLP
LandOfFree
Methods of performing vagal-induced asystole does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of performing vagal-induced asystole, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of performing vagal-induced asystole will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3099037